- Category
- pharma
- Made by
- Helix Biotech
- Tier
- Silver
Overview
Cascade is the daily anti-anxiety regimen Helix Pharma sells to the body whose generalized dread has been classified, in Helix's own clinical literature, as Persistent Cascade Affect Disorder. The product is administered as a single tablet per day from a surgical-white pharmaceutical bottle, and its function is, by Helix's stated specification, to bring the patient's affect profile to clinical baseline. Helix's marketing department announced in 2168 that the brand was reclaiming the word Cascade from the lexicon of trauma and returning it to the lexicon of relief. The prescription volume since launch suggests the reclamation is also profitable.
The product was reformulated in 2174 to include a calibrated affective suppression component descended from AISHA's gentle-sedation pharmaceutical data, acquired through Aftershock integration. The lineage is documented at Level 4 classification and is not advertised. Helix's product literature describes the reformulation as "improved affective fluency." Sauer's files describe it as "AISHA's compound at half-strength, with telemetry." Both descriptions are, in their respective registers, accurate. The patient is not asked to remember the event the brand was named after; the patient is asked to comply with the regimen the brand has built around it.
Packaging & Appearance
A surgical-white pharmaceutical pill bottle with the Helix double-helix etched in deep green on the side wall, and a single tablet visible through a clinical dosing window. The cap wears a soft cyan halo where the neural-handshake antenna sits; the halo brightens at proximity to the patient's biometric profile and dims after the dose is dispensed. The label is dense with regulatory text in three font sizes and includes a QR code linking to a 47-page formulation document available only to credentialed clinicians under NDA. The bottle is engineered to be photographed at the edge of a sterile counter, beside a translucent readout displaying the patient's affect-profile baseline; that is the canonical moment.
Ingredients
Helix Affect Matrix v3.0 (proprietary; full composition disclosed only to credentialed clinicians under NDA — calibrated affective suppression compound, dread-resolution cofactors, AISHA-derivative compounds at safe dosages). Neural-handshake activation (single-use, ingestion-grade). Compliance telemetry (passive, continuous, ninety-day retention). Quarterly regimen subscription with automatic renewal.
Unverified Intelligence
Unverified · in-world intelligence
At least two Helix clinical researchers involved in the 2174 reformulation filed internal objections over the AISHA-derivative compound's provenance. Neither is listed in current Helix staff directories.
An analysis circulating in off-grid pharmaceutical networks claims the neural-handshake telemetry includes passive emotional-state logging beyond the disclosed affect-profile baseline. Helix has issued no denial. Helix rarely issues denials.
The Persistent Cascade Affect Disorder classification appears in no external psychiatric literature prior to 2166 — two years before the product launch announcement. The classification and the product appear to have been developed simultaneously.
Prescription rates correlate with proximity to Helix Clinic infrastructure at a coefficient Helix's own epidemiology team flagged internally as statistically anomalous. The flagged memo was routed to the legal department. No further internal record exists.
Marketing
